Open-label Study of Exjade in the Treatment of Transfusion-dependent Iron Overload in Aplastic Anemia Patients Undergoing Treatment Programs in Comparison With Control Group
Safety and Efficacy of Exjade in the Treatment of Transfusion-dependent Iron Overload in Aplastic Anemia Patients
Sponsors
Source
Novartis
Oversight Info
Has Dmc
Yes
Is Fda Regulated Drug
No
Is Fda Regulated Device
No
Brief Summary
Evaluated Exjade efficacy and safety in patients with aplastic anemia and
transfusion-dependent iron overload, undergoing treatment programs of immunosuppressive
treatment (Cyclosporine A) , in comparison with a group of patients undergoing treatment
programs of immunosuppressive treatment (Cyclosporine A) without chelation therapy.
Detailed Description
The secondary endpoints that were originally planned for this study were not analyzed as the
study ended prematurely.
Overall Status
Terminated
Start Date
2014-06-23
Completion Date
2016-10-17
Primary Completion Date
2016-10-17
Phase
Phase 4
Study Type
Interventional
Primary Outcome
Measure |
Time Frame |
|
Change in Serum Ferritin Values |
Screening, Week (Wk) 4, Wk 8, Wk 12, Wk 16, Wk 20, Wk 24, Wk 28, Wk 32, Wk 36, Wk 40, Wk 44, Wk 48, Wk 52 |
|
Change in Transferrin Saturation With Iron (TSI) Values |
Screening, Week (Wk) 4, Wk 8, Wk 12, Wk 16, Wk 20, Wk 24, Wk 28, Wk 32, Wk 36, Wk 40, Wk 44, Wk 48, Wk 52 |
|
Change in Serum Total Iron-binding Capacity (TIBC) |
Screening, Week (Wk) 4, Wk 8, Wk 12, Wk 16, Wk 20, Wk 24, Wk 28, Wk 32, Wk 36, Wk 40, Wk 44, Wk 48, Wk 52 |
Enrollment
15
Condition
Intervention
Intervention Type
Drug
Intervention Name
Description
ICL670 was supplied in registered packages as 250mg or 500mg dispersible tablets.
Arm Group Label
Serum ferritin level ≥ 1,000 μg/l
Other Name
Deferasirox
Intervention Type
Drug
Intervention Name
Description
Main group of patients with aplastic anemia and transfusion-dependent iron overload underwent treatment programs of standard immunosuppressive treatment (immunosupressant - Cyclosporine A) and received chelation with ICL670 (deferasirox).
Arm Group Label
Serum ferritin level ≥ 1,000 μg/l
Intervention Type
Drug
Intervention Name
Description
Comparative group of patients with aplastic anemia and transfusion-dependent iron overload underwent treatment programs of standard immunosuppressive treatment ( immunosupressant -Cyclosporine A)
Arm Group Label
Serum ferritin level < 1,000 μg/l
Eligibility
Criteria
Inclusion Criteria:
- Main diagnosis: aplastic anemia
- Absence of severe and/or uncontrolled comorbidities
- Confirmed iron overload (serum ferritin ≥ 1000 mkg/L)
- Serum creatinine is not higher than the upper limit of normal for the given age
- Absence of severe proteinuria. Protein/Creatinine ratio should be < 0.5 mg/mg
- Liver enzymes are < 5 ULN
- Completion of a scheduled cycle of immunosuppressive treatment program, with no severe
infectious or generalized hemorrhagic complications
- WHO (ECOG) performance status ≤ 2
Exclusion Criteria:
- No signed informed consent form
- Patient is under 18 years old
- Severe concomitant condition
- Severe infectious and generalized haemorrhagic complication following regular planned
cycle of programmed immune suppressive treatment.
- History of increased sensitivity to active substance and any other ingredient of the
medicinal product.
- Creatinine clearance (CC) < 60 ml/min and/or creatinine concentration in blood serum
is 2 or more times higher than upper limit of age normal by results of 2 tests at
Visits 1 and 2.
- Severe liver disorders (class C by Child-Pugh scale).
- Patients with aplastic anaemia in which chelator treatment will be ineffective due to
rapid progression of the disease.
- Significant proteinuria basing on protein creatinine ratio > 1.0 mg/ml in urine sample
from second urination at Visits 1 and 2 (or as an alternative in 2 of 3 urine samples
at screening);
- Rare hereditary disorders related to galactose intolerance, severe deficit of lactase
or glucose-galactose malabsorption;
- Pregnancy, lactation;
- Level of liver enzymes higher than 5 upper limits of age normal at Visits 1 and 2.
Gender
All
Minimum Age
18 Years
Maximum Age
N/A
Healthy Volunteers
No
Overall Official
Last Name |
Role |
Affiliation |
|
Novartis Pharmaceuticals |
Study Director |
Novartis Pharmaceuticals |
Location
Facility |
|
Novartis Investigative Site Moscow 125167 Russian Federation |
Location Countries
Country
Russian Federation
Verification Date
2019-07-01
Lastchanged Date
N/A
Firstreceived Date
N/A
Responsible Party
Responsible Party Type
Sponsor
Keywords
Has Expanded Access
No
Condition Browse
Number Of Arms
2
Intervention Browse
Mesh Term
Iron
Cyclosporine
Cyclosporins
Immunosuppressive Agents
Deferasirox
Arm Group
Arm Group Label
Serum ferritin level ≥ 1,000 μg/l
Arm Group Type
Experimental
Description
Transfusion-dependent adult patients with AA and serum ferritin ≥ 1000 mg/L on programmed immune suppressive treatment with cyclosporine A who were receiving chelation with Exjade (deferasirox) during the study
Arm Group Label
Serum ferritin level < 1,000 μg/l
Arm Group Type
Experimental
Description
Transfusion-dependent adult patients with AA and serum ferritin < 1,000 mg/L on programmed immune suppressive treatment with cyclosporine A who were not receiving the investigational product
Firstreceived Results Date
N/A
Why Stopped
Failure to meet the schedule of patient recruitment
Patient Data
Sharing Ipd
Yes
Ipd Description
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Firstreceived Results Disposition Date
N/A
Study Design Info
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
None (Open Label)
Study First Submitted
March 5, 2013
Study First Submitted Qc
March 25, 2013
Study First Posted
March 26, 2013
Last Update Submitted
July 8, 2019
Last Update Submitted Qc
July 8, 2019
Last Update Posted
August 16, 2019
Results First Submitted
March 11, 2019
Results First Submitted Qc
July 8, 2019
Results First Posted
August 16, 2019
ClinicalTrials.gov processed this data on February 28, 2020
Conditions
Conditions usually refer to a disease, disorder, syndrome, illness, or injury. In ClinicalTrials.gov,
conditions include any health issue worth studying, such as lifespan, quality of life, health risks, etc.
Interventions
Interventions refer to the drug, vaccine, procedure, device, or other potential treatment being studied.
Interventions can also include less intrusive possibilities such as surveys, education, and interviews.
Study Phase
Most clinical trials are designated as phase 1, 2, 3, or 4, based on the type of questions
that study is seeking to answer:
In Phase 1 (Phase I) clinical trials, researchers test a new drug or treatment in a small group of people (20-80) for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
In Phase 2 (Phase II) clinical trials, the study drug or treatment is given to a larger group of people (100-300) to see if it is effective and to further evaluate its safety.
In Phase 3 (Phase III) clinical trials, the study drug or treatment is given to large groups of people (1,000-3,000) to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
In Phase 4 (Phase IV) clinical trials, post marketing studies delineate additional information including the drug's risks, benefits, and optimal use.
These phases are defined by the Food and Drug Administration in the Code of Federal Regulations.
In Phase 1 (Phase I) clinical trials, researchers test a new drug or treatment in a small group of people (20-80) for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
In Phase 2 (Phase II) clinical trials, the study drug or treatment is given to a larger group of people (100-300) to see if it is effective and to further evaluate its safety.
In Phase 3 (Phase III) clinical trials, the study drug or treatment is given to large groups of people (1,000-3,000) to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
In Phase 4 (Phase IV) clinical trials, post marketing studies delineate additional information including the drug's risks, benefits, and optimal use.
These phases are defined by the Food and Drug Administration in the Code of Federal Regulations.